STAT Breakthrough Summit West
Coverage of STAT Breakthrough Summit West in the Nexus archive.
- STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Retro Biosciences, a longevity startup backed by OpenAI CEO Sam Altman, has raised funding at a $1.8 billion valuation. The company aims to add 10 healthy years to human lifespan through gene therapies and cell replacement therapies. The company is currently running its first clinical trial for an Alzheimer's disease treatment, with positive results and data expected around August.
- Guarding biotech from China and big bets in longevity
STAT's Breakthrough Summit West brought together leaders in healthcare and science to discuss biotech developments. Key topics included BridgeBio's research publication concerns and Retro Biosciences' progress toward clinical trials, with focus on AI's role in drug development.
- Are ‘AI co-scientist’ tools actually useful for scientists?
STAT's AI Prognosis newsletter explores the practical utility of AI co-scientist tools for researchers in healthcare and medicine. The article references panels from the STAT Breakthrough Summit West in San Francisco where experts discussed applications of artificial intelligence in scientific research.
- STAT+: Biotech execs, academic expert lament impact of FDA turnover on rare disease drug development
Biotech executives and an academic expert discuss the impact of FDA turnover on rare disease drug development, citing anxiety and uncertainty. Mahzi Therapeutics CEO Yael Weiss shares her experience with investor concerns. The debate focuses on the flexibility the FDA should allow in clinical trial design.
- STAT+: OpenEvidence makes its pitch to hospitals. ‘We’re not crazy monsters’
OpenEvidence has built a free chatbot for doctors and achieved a $12 billion valuation in four years, with about 650,000 U.S. physicians using it actively. The company is now facing competitive pressures and questions about its ad-based business model. OpenEvidence is aiming to expand its reach to hospitals.
- STAT+: Dexcom CEO hints at future uses for CGM
Dexcom CEO hints at future uses for CGM, and the author is attending the STAT Breakthrough Summit West in San Francisco. The summit features interviews with key figures like OpenEvidence CTO Zachary Ziegler. Readers can follow coverage on Statnews.com and social channels.